ICON

Icon makes senior appointments

Monday, May 21, 2012 11:52 AM

Icon, a global provider of outsourced development services, has appointed Dr. Susan Anton as director of epidemiology and risk management practice, Icon late phase & outcomes research, and Dr. Pui Leung as senior clinical research physician, Icon Development Solutions.

More... »


J&J China acquires Guangzhou Bioseal Biotech

Friday, May 4, 2012 08:01 AM

Johnson & Johnson China Investment has acquired Guangzhou Bioseal Biotech, a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery. Financial terms of the transaction are not being disclosed. 

More... »


Icon reports 10% increase in Q1 2012

Wednesday, April 25, 2012 09:45 AM

Icon, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has released its first quarter financial results for 2012, reporting its Q1 net revenues grew 10% year on year to $252.3 million from $229.3 million in Q1 2011.

More... »

ICON, Roche in technology partnership

Tuesday, March 6, 2012 01:27 PM

Global CRO ICON has been selected by Roche as its technology partner for storing and managing medical images collected during the company’s clinical research programs.

More... »

J&J’s Alex Gorsky succeeds Bill Weldon as CEO

Saturday, February 25, 2012 06:34 AM

Johnson & Johnson’s board of directors has named Alex Gorsky CEO of J&J effective April 26, 2012, the date of the company’s annual meeting of shareholders.  

More... »

ICON reports quarterly revenue up 5%

Friday, February 17, 2012 01:43 PM

ICON,a global CRO, has reported financial results for the full year and for the fourth quarter ending Dec. 31, 2011.

More... »

Premier Research names Drouet executive director, Oncology Europe

Monday, January 23, 2012 12:36 PM

Premier Research Group has appointed Etienne Drouet executive director, Oncology Europe. Drouet will play a leading role in the operations, strategic planning and corporate development of Premier Research’s growing portfolio of oncology businesses.

More... »

Lexicon’s LX411 enhances DPP-4 inhibitor in type 2 diabetics

Friday, January 13, 2012 12:09 PM

LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, was proven to enhance the affects of widely prescribed diabetes drug sitagliptin, a DDP-4 (dipeptidyl peptidase) inhibitor, reported Lexicon Pharmaceuticals.

More... »

ICON named sole provider of central lab services to Shire

Monday, January 9, 2012 01:45 PM

CRO ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

More... »

Icon boosts its presence in Asia with acquisition of Chinese CRO BeijingWits Medical Consulting

Monday, December 19, 2011 10:13 AM

Now that many mid-tier CROs have been acquired by either equity investment firms or other CROs and the trend has slowed, a new form of consolidation is emerging. Robust CROs are rounding out their offerings with small but strategic acquisitions to make them bigger, stronger and more complete. The ultimate goal: to continue winning lucrative strategic outsourcing agreements from sponsors.  

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs